Drug Interactions with Coumarin Anticoagulants

New England Journal of Medicine

Volumn 285, Issue 10, 1971, Pages 547-558

  Koch Weser, Jan ^a   Sellers, Edward M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ALLOPURINOL; ANABOLIC AGENT; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; BARBITURIC ACID DERIVATIVE; CHLORAL HYDRATE; CHLORAMPHENICOL; CLOFIBRATE; COLESTYRAMINE; COUMARIN DERIVATIVE; DEXTROTHYROXINE; DIURETIC AGENT; ETACRYNIC ACID; GLUCAGON; GLUCOCORTICOID; GLUTETHIMIDE; ORAL CONTRACEPTIVE AGENT; OXYPHENBUTAZONE; PHENYLBUTAZONE; QUINIDINE; QUININE; QUINOLINE DERIVATIVE; SALICYLIC ACID DERIVATIVE; SULFINPYRAZONE; SULFONAMIDE; THYROID HORMONE; TOLBUTAMIDE;

ANIMAL; DRUG ANTAGONISM; DRUG POTENTIATION; HUMAN; REVIEW;

ALLOPURINOL; ANABOLIC STEROIDS; ANIMAL; ANTIBIOTICS; ANTICOAGULANTS; BARBITURATES; CHLORAL HYDRATE; CHLORAMPHENICOL; CHOLESTYRAMINE; CLOFIBRATE; CONTRACEPTIVES, ORAL; COUMARINS; DEXTROTHYROXINE; DIURETICS; DRUG ANTAGONISM; DRUG SYNERGISM; ETHACRYNIC ACID; ETHANOL; GLUCAGON; GLUCOCORTICOIDS; GLUTETHIMIDE; HUMAN; OXYPHENBUTAZONE; PHENYLBUTAZONE; QUINIDINE; QUININE; QUINOLINES; SALICYLATES; SULFINPYRAZONE; SULFONAMIDES; THYROID HORMONES; TOLBUTAMIDE;

EID: 0015208247     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM197109022851005     Document Type: Review

References (86)

1. Antlitz AM, Mead JA Jr, Tolentino MA: Potentiation of oral anticoagulant therapy by acetaminophen. Curr Ther Res 10: 501–507, 1968
2. Antlitz AM, Awalt LF: A double blind study of acetaminophen used in conjunction with oral anticoagulant therapy. Curr Ther Res 11: 360–361, 1969
3. Udall JA: Drug interference with warfarin therapy. Clin Med 77 (8):20–25, 1970
4. Chatterjea JB, Salomon L: Antagonistic effect of A.C.T.H. and cortisone on the anticoagulant activity of ethyl biscoumacetate. Br Med J 2: 790–792, 1954
5. Menczel J, Dreyfuss F: Effect of prednisone on blood coagulation time in patients on Dicumarol therapy. J Lab Clin Med 56: 14–20, 1960
6. Ozsoylu S, Strauss HS, Diamond LK: Effects of corticosteroids on coagulation of the blood. Nature (Lond) 195: 1214–1215, 1962
7. Pyörälä K, Kekki M: Decreased anticoagulant tolerance during methandrostenolone therapy. Scand J Clin Lab Invest 15: 367–374, 1963
8. Murakami M, Odake K, Matsuda T, et al: Effects of anabolic steroids on anticoagulant requirements. Jap Circ J 29: 243–250, 1965
9. Dresdale FC, Hayes JC: Potential dangers in the combined use of methandrostenolone and sodium warfarin. J Med Soc NJ 64: 609–612, 1967
10. Schrogie JJ, Solomon HM: The anticoagulant response to bishydroxycoumarin. II. The effect of D-thyroxine, clofibrate and norethandrolone. Clin Pharmacol Ther 8: 70–77, 1967
11. Pyörälä K, Myllylä G, Kekki M: Metabolism of warfarin during methandrostenolone treatment. Ann Med Exp Biol Fenn 43: 95–97, 1965
12. Messinger WJ, Samet CM: The effect of a bowel sterilizing antibiotic on blood coagulation mechanisms: the anti-cholesterol effect of paromomycin. Angiology 16: 29–36, 1965
13. Magid E: Tolerance to anticoagulants during antibiotic therapy. Scand J Clin Lab Invest 14: 565–566, 1962
14. Faloon WW, Paes IC, Woolfolk D, et al: Effect of neomycin and kanamycin upon intestinal absorption. Ann NY Acad Sci 132: 879–887, 1966
15. Grilli H: Gluthetimida y tiempo de protrombina: su aplicación en la terapéutica anticoagulante. Prensa Med Argent 46: 2867–2869, 1959
16. Reverchon F, Sapir M: Constatation clinique d'un antagonisme entre barbituriques et anticoagulants. Presse Med 69: 1570–1571, 1961
17. Robinson DS, Sylwester D: Interaction of commonly prescribed drugs and warfarin. Ann Intern Med 72: 853–856, 1970
18. Ikeda M, Conney AH, Burns JJ: Stimulatory effect of phenobarbital and insecticides on warfarin metabolism in the rat. J Pharmacol Exp Ther 162: 338–343, 1968
19. Levy G, O'Reilly RA, Aggeler PM, et al: Pharmacokinetic analysis of the effect of barbiturate on the anticoagulant action of warfarin in man. Clin Pharmacol Ther 11: 372–377, 1970
20. Corn M, Rockett JF: Inhibition of bishydroxycoumarin activity by phenobarbital. Med Ann DC 34: 578–579, 588, 1965
21. Goss JE, Dickhaus DW: Increased bishydroxycoumarin requirements in patients receiving phenobarbital. N Engl J Med 273: 1094–1095, 1965
22. Van Dam FE,, Gribnau-Overkamp MJH: The effect of some sedatives (phenobarbital, glutethimide, chlordiazepoxide, chloral hydrate) on the rate of disappearance of ethyl biscoumacetate from the plasma. Folia Med Neerl 10: 141–145, 1967
23. Weiner M: Effect of centrally active drugs on the action of coumarin anticoagulants. Nature (Lond) 212: 1599–1600, 1966
24. Lucas ON: Study of the interaction of barbiturates and Dicumarol and their effect on prothrombin activity, hemorrhage, and sleeping time in rats. Can J Physiol Pharmacol 45: 905–913, 1967
25. Hunninghake DB, Azarnoff DL: Drug interactions with warfarin. Arch Intern Med 121: 349–352, 1968
26. Martin YC: The effect of ethchlorvynol on the drug-metabolizing enzymes of rats and dogs. Biochem Pharmacol 16: 2041–2044, 1967
27. Welch RM, Harrison YE, Conney AH et al: An experimental model in dogs for studying interactions of drugs with bishydroxycoumarin. Clin Pharmacol Ther 10: 817–825, 1969
28. Lackner H, Hunt VE: The effect of Librium on hemostasis. Am J Med Sci 256: 368–372, 1968
29. Matis P: Toleranzänderungcn (Effekte von Nebenmedikamenten) bei langzeitiger Antikoagulantienbehandlung. Thromb Diath Hemorrh [Suppl] 12: 33–38, 1964
30. Cucinell SA, Odessky L, Weiss M, et al: The effect of chloral hydrate on bishydroxycoumarin metabolism: a fatal outcome. JAMA 197: 366–368, 1966
31. Gross L, Brotman M: Hypoprothrombinemia and hemorrhage associated with cholestyramine therapy. Ann Intern Med 72: 95–96, 1970
32. Oliver MF, Roberts SD, Hayes D, et al: Effect of atromid and ethyl chlorophenoxyisobutyrate on anticoagulant requirements. Lancet 1: 143–144, 1963
33. Counihan TB, Keelan P: Atromid in high cholesterol states. J Atheroscler Res 3: 580–583, 1963
34. Roberts SD, Pantridge JF: Effect of atromid on requirements of warfarin. J Atheroscler Res 3: 655–657, 1963
35. Hellman L, Zumoff B, Kessler G, et al: Reduction of cholesterol and lipids in man by ethyl p-chlorophenoxyisobutyrate. Ann Intern Med 59: 477–494, 1963
36. Jones RJ, Cohen L: Sodium dextro-thyroxine in coronary disease and hypercholesteremia. Circulation 24: 164–170, 1961
37. Owens JC, Neely WB, Owen WR: Effect of sodium dextrothyroxine in patients receiving anticoagulants. N Engl J Med 266: 76–79, 1962
38. Dufault C, Tremblay G, Nowaczynski W, et al: Influence of dextro-thyroxine and androsterone on blood clotting factors and serum cholesterol in patients with atherosclerosis. Can Med Assoc J 85: 1025–1031, 1961
39. Rothstein E: Warfarin effect enhanced by disulfiram. JAMA 206: 1574–1575, 1968
40. Buu-Hoï NP, Hien DP, Hoi T-T: Effets de deux diurétiques, l'hydrochlorothiazide et l'acide éthacrynique sur la coagulation sanguine chez le rat normal et chez le rat recevant des antivitamines K. C R Acad Sci [D] (Paris) 265: 2165–2167, 1967
41. Egeberg O: The effect of edema drainage on the blood clotting system. Scand J Clin Lab Invest 15: 14–19, 1963
42. Vinazzer H: Die Beeinflussung der Antikoagulantientherapie durch ein Diuretikum. Wien Z Inn Med 44: 323–327, 1963
43. O'Reilly RA, Sahud MA, Aggeler PM: Impact of aspirin and chlorthalidone on the pharmacodynamics of oral anticoagulant drugs in man. Ann NY Acad Sci 179: 173–186, 1971
44. Waris E: Effect of ethyl alcohol on some coagulation factors in man during anticoagulant therapy. Ann Med Exp Fenn 41: 45–53, 1963
45. Riedler G: Einfluss des Alkohols auf die Antikoagulantientherapie. Thromb Diath Haemorrh 16: 613–635, 1966
46. Kater RMH, Roggin G, Tobon F, et al: Increased rate of clearance of drugs from the circulation of alcoholics. Am J Med Sci 258: 35–39. 1969
47. Cullen SI, Catalano PM: Griseofulvin-warfarin antagonism. JAMA 199: 582–583, 1967
48. Weiner M, Moses D: The effect of glucagon and insulin on the prothrombin response to coumarin anticoagulants. Proc Soc Exp Biol Med 127: 761–763, 1968
49. Müller KH, Herrmann K: Verträgt sich eine gleichzeitige Behandlung mit Antikoagulantien und Indometacin? Med Welt 17: 1553–1554, 1966
50. Gáspárdy G, Bálint G, Gáspárdy G Jr: Wirkung der Kombination Indomethacin und Syncumar (Acenocumarol) auf den Prothrombinspiegel im Blutplasma. Z Rheumaforsch 26: 332–335, 1967
51. Holmes EL: Pharmacology of the fenamates: IV. Toleration by normal human subjects. Ann Phys Med [Suppl] 8: 36–49, 1966
52. Buu-Hoï NP, Hien DP: Potentiation of the anticoagulant effects of antivitamins K by 6-mercaptopurine. Naturwissenschaften 55: 134, 1968
53. Garrettson LK, Perel JM, Dayton PG: Methylphenidate interaction with both anticonvulsants and ethyl biscoumacelate: a new action of methylphenidate. JAMA 207: 2053–2056, 1969
54. Hrdina P, Rusnáková M, Kovalčík V: Changes of hypoprothrombinaemic activity of indirect anticoagulants after MAO inhibitors and reserpine. Biochem Pharmacol 12: Suppl 1: 241–242, 1963
55. Fumarola D, DeRinaldis P: Ricerche sperimentali sugli inibitori della mono-aminossidasi. Haematologica 49: 1248–1266, 1964
56. DeNicola P, Fumarola D, DeRinaldis P: Beeinflussung der gerinnungshemmenden Wirkung der indirekten Antikoagulantien durch die MAO-Inhibitoren. Thromb Diath Haemorrh [Suppl] 12: 125–127, 1964
57. Reber K, Studer A: Beeinflussung der Wirkung einiger indirekter Antikoagulantien durch Monoaminoxydase-Hemmer. Thromb Diath Haemorrh 14: 83–87, 1965
58. Shimamoio T, Takeuchi K, Ishioka T: Preventive effectiveness of MAO inhibitor and ineffectiveness of prothrombinopenic anticoagulant against increase in plasma thrombin activity by adrenaline, cholesterol, and traumatization. Am Heart J 64: 71–78, 1962
59. Schrogie JJ, Solomon HM, Zieve PD: Effect of oral contraceptives on vitamin K-dependent clotting activity. Clin Pharmacol Ther 8: 670–675, 1967
60. Poller L, Thomson JM, Tabiowo A, et al: Progesterone oral contraception and blood coagulation. Br Med J 1: 554–556, 1969
61. Sigg A, Pestalozzi H, Clauss A, et al: Verstärkung der Antikoagulantienwirkung durch Butazolidin. Schweiz Med Wochenschr 86: 1194–1195, 1956
62. Hobbs CB, Miller AL, Thornley JH: Potentiation of anticoagulant therapy by oxyphenylbutazone: (a probable case). Postgrad Med J 41: 563–565, 1965
63. O'Reilly RA, Aggeler PM: Phenylbutazone potentiation of anticoagulant effect: fluorometric assay of warfarin. Proc Soc Exp Biol Med 128: 1080–1081, 1968
64. O'Reilly RA, Levy G: Pharmacokinetic analysis of potentiating effect of phenylbutazone on anticoagulant action of warfarin in man. J Pharm Sci 59: 1258–1261, 1970
65. Bobek K, Horáková Z, Čepelák V: Arzneibedingte Blutungen bei Behandlung mit Pyrazolonen und Antikoagulantien. Z Gesamte Inn Med 20: Suppl: 309–311, 1965
66. Seiler K, Duckert F: Properties of 3-(1-phenyl-propyl)-4-oxycoumarin (Marcoumar®) in the plasma when tested in normal cases and under the influence of drugs. Thromb Diath Haemorrh 19: 389–396, 1968
67. O'Reilly RA: Mechanisms for warfarin-phenylbutazone interaction in man and dog. Clin Res 18: 177, 1970
68. Carter SA: Potentiation of the effect of orally administered anticoagulants by phenyramidol hydrochloride. N Engl J Med 273: 423–426. 1965
69. Solomon HM, Schrogie JJ: The effect of phenyramidol on the metabolism of bishydroxycoumarin. J Pharmacol Exp Ther 154: 660–666, 1966
70. Koch-Weser J: Quinidine-induced hypoprothrombinemic hemorrhage in patients on chronic warfarin therapy. Ann Intern Med 68: 511–517, 1968
71. Gazzaniga AB, Stewart DR: Possible quinidine-induced hemorrhage in a patient on warfarin sodium. N Engl J Med 280: 711–712, 1969
72. Beaumont JL, Tarrit A: Les accidents hemorragiques survenus au cours de 1500 traitements anticoagulants. Sang 26: 680–694, 1955
73. Jarnum S: Cinchophen and acetylsalicylic acid in anticoagulant treatment. Scand J Lab Clin Invest 6: 91–93, 1954
74. Rapoport S, Wing M, Guest GM: Hypoprothrombinemia after salicylate administration in man and rabbits. Proc Soc Exp Biol Med 53: 40–41, 1943
75. Quick AJ, Clesceri L: Influence of acetylsalicylic acid and salicylamide on the coagulation of blood. J Pharmacol Exp Ther 128: 95–98, 1960
76. Link KP, Overman RS, Sullivan WR, et al: Studies on the hemorrhagic sweet clover disease. XI. Hypoprothrombinemia in the rat induced by salicylic acid. J Biol Chem 147: 463–474, 1943
77. Watson RM, Pierson RN Jr: Effect of anticoagulant therapy upon aspirin-induced gastrointestinal bleeding. Circulation 24: 613–616, 1961
78. Walters MB: The relationship between thyroid function and anticoagulant therapy. Am J Cardiol 11: 112–114, 1963
79. Lowenthal J, Fisher LM: The effect of thyroid function on the prothrombin time response to warfarin in rats. Experientia 13: 253–254, 1957
80. Chaplin H Jr, Cassell M: Studies on the possible relationship of tolbutamide to Dicumarol in anticoagulant therapy. Am J Med Sci 235: 706–716, 1958
81. Poucher RL, Vecchio TJ: Absence of tolbutamide effect on anticoagulant therapy. JAMA 197: 1069–1070, 1966
82. Kristensen M, Hansen JM: Accumulation of chlorpropamide caused by dicoumarol. Acta Med Scand 183: 83–86, 1968
83. Hansen JM, Kristensen M, Skovsted L: Dicoumarol-induced diphenylhydantoin intoxication. Lancet 2: 265–266, 1966
84. Kristensen M, Hansen JM: Potentiation of the tolbutamide effect by dicoumarol. Diabetes 16: 211–214, 1967
85. Solomon HM, Schrogie JJ: Effect of phenyramidol and bishydroxycoumarin on the metabolism of tolbutamide in human subjects. Metabolism 16: 1029–1033, 1967
86. Spurny OM, Wolf JW, Devins GS: Protracted tolbutamide-induced hypoglycemia. Arch Intern Med 115: 53–56, 1965